Sign up for News by Email
All Releases
View Summary Threshold Pharmaceuticals Reports First Quarter Financial Results
May 5, 2016
PDF 26.9 KB
View Summary Threshold Pharmaceuticals Appoints Stew Kroll as Chief Operating Officer
Mar 21, 2016
PDF 11.3 KB
View Summary Threshold Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
Mar 10, 2016
PDF 33.6 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Cowen and Company 36th Annual Health Care Conference
Mar 1, 2016
PDF 11.5 KB
View Summary Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany Agree to Key Terms for the Licensing Back of All Rights to Evofosfamide to Threshold
Jan 11, 2016
PDF 13.9 KB
View Summary Threshold Pharmaceuticals Announces Workforce Reduction
Dec 18, 2015
PDF 13.2 KB
View Summary Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not Meet Primary Endpoints
Dec 7, 2015
PDF 13.3 KB
View Summary Threshold Pharmaceuticals Enters Into Definitive Co-Promotion Agreement for Evofosfamide With Merck KGaA, Darmstadt, Germany
Nov 18, 2015
PDF 13.1 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2015 Healthcare Conference
Nov 11, 2015
PDF 7.8 KB
View Summary Preclinical Studies Find That Tarloxotinib May Overcome Resistance to EGFR Tyrosine Kinase Inhibitors
Nov 6, 2015
PDF 21.9 KB
View Summary Threshold Pharmaceuticals Announces Preclinical Data on Combination of Evofosfamide With Immune Checkpoint Inhibitors to Be Presented at the SITC 2015 Meeting
Nov 3, 2015
PDF 14.2 KB
View Summary Threshold Pharmaceuticals Reports Third Quarter 2015 Financial and Operational Results
Nov 2, 2015
PDF 24.0 KB
View Summary Threshold Pharmaceuticals Announces Preclinical Data Presentations on Tarloxotinib at the 2015 AACR-NCI-EORTC Meeting
Oct 27, 2015
PDF 19.6 KB
View Summary Threshold Pharmaceuticals Receives Two U.S. Patents for Tarloxotinib Bromide
Oct 13, 2015
PDF 19.4 KB
View Summary Threshold Pharmaceuticals Appoints Mark Hopkins, J.D., Ph.D., Vice President of Intellectual Property and Assistant General Counsel
Sep 8, 2015
PDF 16.2 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw Annual Global Investment Conference
Sep 3, 2015
PDF 7.8 KB
View Summary Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin
Aug 27, 2015
PDF 55.7 KB
View Summary Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC)
Aug 11, 2015
PDF 14.7 KB
View Summary Threshold Pharmaceuticals Reports Second Quarter 2015 Financial and Operational Results
Jul 30, 2015
PDF 26.0 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Cantor Fitzgerald Healthcare Conference
Jul 1, 2015
PDF 7.8 KB
Showing 1-20 of 288 Page: 1 2 3 4 5 ... 15  Next 20
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue